Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Oct;66(4):680–684. doi: 10.1038/bjc.1992.337

Contribution of 3H-thymidine labelling index and flow cytometric S-phase in predicting survival of patients with non-Hodgkin's lymphoma.

A Costa 1, R Silvestrini 1, R Giardini 1, G Messina-Gabrielli 1, P Boracchi 1, S Veneroni 1
PMCID: PMC1977419  PMID: 1419606

Abstract

The 3H-thymidine labelling index (3H-dT LI) of cell suspensions from fresh material and the flow cytometric S-phase (FCM-S) of nuclei recovered from paraffin blocks were determined on the same pathologic lymph node specimen for 190 non-Hodgkin's lymphomas (NHLs). FCM-S was defined by a planimetric method and by an optimization procedure. Poor correlation coefficients were observed among the three cell kinetic variables. All three cell kinetic variables were significant indicators of 8-year survival and median survival time. The life-regression procedure evidenced a significant relative contribution of 3H-dT LI and FCM-S, thus suggesting a different biologic meaning of the two cell kinetic variables. This finding was further supported by evidence that simultaneous use of 3H-dT LI and FCM-S can identify groups of patients with different survival better than when either modality is used alone. Multivariate analysis indicated that the risk groups as defined by cell kinetic variables are predictors of survival even in the presence of established factors such as histology and stage.

Full text

PDF
680

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bajetta E., Valagussa P., Bonadonna G., Lattuada A., Buzzoni R., Rilke F., Banfi A. Combined modality treatment for stage I-II non-Hodgkin's lymphomas: CVP versus BACOP chemotherapy. Int J Radiat Oncol Biol Phys. 1988 Jul;15(1):3–12. doi: 10.1016/0360-3016(88)90340-9. [DOI] [PubMed] [Google Scholar]
  2. Brandt L., Olsson H., Monti M. Uptake of thymidine in lymphoma cells obtained through fine-needle aspiration biopsy. Relation to prognosis in non-Hodgkin's lymphomas. Eur J Cancer Clin Oncol. 1981 Nov;17(11):1229–1233. [PubMed] [Google Scholar]
  3. Braylan R. C., Diamond L. W., Powell M. L., Harty-Golder B. Percentage of cells in the S phase of the cell cycle in human lymphoma determined by flow cytometry. Cytometry. 1980 Nov;1(3):171–174. doi: 10.1002/cyto.990010302. [DOI] [PubMed] [Google Scholar]
  4. Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860–1861. [PubMed] [Google Scholar]
  5. Christensson B., Tribukait B., Linder I. L., Ullman B., Biberfeld P. Cell proliferation and DNA content in non-Hodgkin's lymphoma. Flow cytometry in relation to lymphoma classification. Cancer. 1986 Sep 15;58(6):1295–1304. doi: 10.1002/1097-0142(19860915)58:6<1295::aid-cncr2820580620>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  6. Costa A., Bonadonna G., Villa E., Valagussa P., Silvestrini R. Labeling index as a prognostic marker in non-Hodgkin's lymphomas. J Natl Cancer Inst. 1981 Jan;66(1):1–5. [PubMed] [Google Scholar]
  7. Costa A., Silvestrini R., Mezzanotte G., Vaglini M., Grignolio E., Clemente C., Cascinelli N. Cell kinetics: an independent prognostic variable in stage II melanoma of the skin. Br J Cancer. 1990 Nov;62(5):826–829. doi: 10.1038/bjc.1990.386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Grierson H. L., Wooldridge T. N., Purtilo D. T., Pierson J., Bast M., Wooldridge L., Armitage J. O., Weisenburger D. D. Low proliferative activity is associated with a favorable prognosis in peripheral T-cell lymphoma. Cancer Res. 1990 Aug 15;50(16):4845–4848. [PubMed] [Google Scholar]
  9. Griffin N. R., Howard M. R., Quirke P., O'Brien C. J., Child J. A., Bird C. C. Prognostic indicators in centroblastic-centrocytic lymphoma. J Clin Pathol. 1988 Aug;41(8):866–870. doi: 10.1136/jcp.41.8.866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hedley D. W., Friedlander M. L., Taylor I. W., Rugg C. A., Musgrove E. A. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem. 1983 Nov;31(11):1333–1335. doi: 10.1177/31.11.6619538. [DOI] [PubMed] [Google Scholar]
  11. Joensuu H., Klemi P. J., Jalkanen S. Biologic progression in non-Hodgkin's lymphoma. A flow cytometric study. Cancer. 1990 Jun 1;65(11):2564–2571. doi: 10.1002/1097-0142(19900601)65:11<2564::aid-cncr2820651128>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  12. Kvaløy S., Marton P. F., Kaalhus O., Høie J., Foss-Abrahamsen A., Godal T. 3H-thymidine uptake in B cell lymphomas--relationship to treatment response and survival. Scand J Haematol. 1985 May;34(5):429–435. doi: 10.1111/j.1600-0609.1985.tb00773.x. [DOI] [PubMed] [Google Scholar]
  13. Lenner P., Roos G., Johansson H., Lindh J., Dige U. Non-Hodgkin lymphoma. Multivariate analysis of prognostic factors including fraction of S-phase cells. Acta Oncol. 1987;26(3):179–183. doi: 10.3109/02841868709091427. [DOI] [PubMed] [Google Scholar]
  14. McGuire W. L., Tandon A. K., Allred D. C., Chamness G. C., Clark G. M. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst. 1990 Jun 20;82(12):1006–1015. doi: 10.1093/jnci/82.12.1006. [DOI] [PubMed] [Google Scholar]
  15. Monfardini S., Banfi A., Bonadonna G., Rilke F., Milani F., Valagussa P., Lattuada A. Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 1980 Feb;6(2):125–134. doi: 10.1016/0360-3016(80)90027-9. [DOI] [PubMed] [Google Scholar]
  16. Monfardini S., Rilke F., Valagussa P., Bajetta E., Canetta R., Buzzoni R., Giardini R., Viviani S. A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classifications. Eur J Cancer Clin Oncol. 1984 May;20(5):609–617. doi: 10.1016/0277-5379(84)90005-1. [DOI] [PubMed] [Google Scholar]
  17. O'Reilly S. M., Camplejohn R. S., Barnes D. M., Millis R. R., Allen D., Rubens R. D., Richards M. A. DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer. 1990 May;61(5):671–674. doi: 10.1038/bjc.1990.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rehn S., Glimelius B., Strang P., Sundström C., Tribukait B. Prognostic significance of flow cytometry studies in B-cell non-Hodgkin lymphoma. Hematol Oncol. 1990 Jan-Feb;8(1):1–12. doi: 10.1002/hon.2900080102. [DOI] [PubMed] [Google Scholar]
  19. Roos G., Dige U., Lenner P., Lindh J., Johansson H. Prognostic significance of DNA-analysis by flow cytometry in non-Hodgkin's lymphoma. Hematol Oncol. 1985 Oct-Dec;3(4):233–242. doi: 10.1002/hon.2900030403. [DOI] [PubMed] [Google Scholar]
  20. Scarffe J. H., Crowther D. The pre-treatment proliferative activity of non-Hodgkin's lymphoma cells. Eur J Cancer. 1981 Jan;17(1):99–108. doi: 10.1016/0014-2964(81)90218-8. [DOI] [PubMed] [Google Scholar]
  21. Schutte B., Reynders M. M., Bosman F. T., Blijham G. H. Flow cytometric determination of DNA ploidy level in nuclei isolated from paraffin-embedded tissue. Cytometry. 1985 Jan;6(1):26–30. doi: 10.1002/cyto.990060106. [DOI] [PubMed] [Google Scholar]
  22. Silvestrini R., Costa A., Giardini R., Boracchi P., Del Bino G., Marubini E., Rilke F. Prognostic implications of cell kinetics, histopathology and pathologic stage in non-Hodgkin's lymphomas. Hematol Oncol. 1989 Nov-Dec;7(6):411–422. doi: 10.1002/hon.2900070604. [DOI] [PubMed] [Google Scholar]
  23. Silvestrini R., Costa A., Veneroni S., Del Bino G., Persici P. Comparative analysis of different approaches to investigate cell kinetics. Cell Tissue Kinet. 1988 Mar;21(2):123–131. doi: 10.1111/j.1365-2184.1988.tb00778.x. [DOI] [PubMed] [Google Scholar]
  24. Silvestrini R., Daidone M. G., Valagussa P., Di Fronzo G., Mezzanotte G., Mariani L., Bonadonna G. 3H-thymidine-labeling index as a prognostic indicator in node-positive breast cancer. J Clin Oncol. 1990 Aug;8(8):1321–1326. doi: 10.1200/JCO.1990.8.8.1321. [DOI] [PubMed] [Google Scholar]
  25. Urba W. J., Duffey P. L., Longo D. L. Treatment of patients with aggressive lymphomas: an overview. J Natl Cancer Inst Monogr. 1990;(10):29–37. [PubMed] [Google Scholar]
  26. Volm M., Brüggemann A., Günther M., Kleine W., Pfleiderer A., Vogt-Schaden M. Prognostic relevance of ploidy, proliferation, and resistance-predictive tests in ovarian carcinoma. Cancer Res. 1985 Oct;45(10):5180–5185. [PubMed] [Google Scholar]
  27. Volm M., Mattern J., Müller T., Drings P. Flow cytometry of epidermoid lung carcinomas: relationship of ploidy and cell cycle phases to survival. A five-year follow up study. Anticancer Res. 1988 Jan-Feb;8(1):105–112. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES